Semorinemab,anti-Tau antibody, in early Alzheimer’s disease fails in Phase II trial.- AC Immune + Genentech Roche.

AC Immune SA announced that Genentech, a member of the Roche Group, has informed the Company of top line results from a Phase II trial of the anti-Tau antibody, semorinemab, in early (prodromal to mild) Alzheimer’s disease (AD) which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo. Two secondary endpoints, Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimer’s Disease Cooperative Study Group – Activities of Daily Living Inventory (ADCS-ADL) were also not met. Additional data analyses are ongoing and Genentech plans to present the results from TAURIEL at an upcoming medical congress. The second Phase II (LAURIET) study of semorinemab in patients with moderate AD remains ongoing.